| pubmed-article:3524418 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0042029 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0042066 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0205052 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0007537 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C0054066 | lld:lifeskim |
| pubmed-article:3524418 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3524418 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3524418 | pubmed:dateCreated | 1986-7-30 | lld:pubmed |
| pubmed-article:3524418 | pubmed:abstractText | In a double-blind randomized study, amoxicillin-clavulanic acid (AM-CL) was compared with cefaclor for the treatment of acute urinary tract infections in 107 college women. A total of 53 patients received amoxicillin (250 mg) and clavulanic acid as the potassium salt (125 mg), and 54 received cefaclor (250 mg); each drug was administered every 8 h for 10 days. The cure rates at 1 and 4 weeks after treatment were 96 and 78%, respectively, in the AM-CL group and 92 and 75%, respectively, in the cefaclor group (P greater than 0.10). After AM-CL treatment, the prevalence of amoxicillin-resistant Escherichia coli significantly increased in the rectal flora. Also, the frequency of bacterial resistance to amoxicillin, AM-CL, and cefaclor increased among the urinary pathogens causing subsequent urinary tract infections (P less than 0.05). There were no adverse reactions in the cefaclor group; however, six patients in the AM-CL group (12%) experienced diarrhea, nausea, or vomiting (P less than 0.05). Elevated transaminase enzyme levels were observed in 23% of the patients in the AM-CL group and in 6% of the patients in the cefaclor group (P less than 0.05). Symptomatic Candida vaginitis developed in 16 and 13% of the patients in the AM-CL and cefaclor groups, respectively (P greater than 0.10). | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3524418 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3524418 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3524418 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3524418 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3524418 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:3524418 | pubmed:author | pubmed-author:RichardG AGA | lld:pubmed |
| pubmed-article:3524418 | pubmed:author | pubmed-author:IravaniAA | lld:pubmed |
| pubmed-article:3524418 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3524418 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:3524418 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3524418 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3524418 | pubmed:pagination | 107-11 | lld:pubmed |
| pubmed-article:3524418 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:meshHeading | pubmed-meshheading:3524418-... | lld:pubmed |
| pubmed-article:3524418 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3524418 | pubmed:articleTitle | Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. | lld:pubmed |
| pubmed-article:3524418 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3524418 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3524418 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:3524418 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3524418 | lld:pubmed |
